Lantern Pharma Inc.
LTRN
$3.74
-$0.19-4.84%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.46M | 1.52M | 1.48M | 1.30M | 1.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.18M | 5.41M | 5.73M | 4.88M | 3.52M |
| Operating Income | -5.18M | -5.41M | -5.73M | -4.88M | -3.52M |
| Income Before Tax | -4.51M | -4.96M | -5.44M | -4.19M | -3.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.51M | -4.96M | -5.44M | -4.19M | -3.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.51M | -4.96M | -5.44M | -4.19M | -3.16M |
| EBIT | -5.18M | -5.41M | -5.73M | -4.88M | -3.52M |
| EBITDA | -5.18M | -5.40M | -5.73M | -4.87M | -3.52M |
| EPS Basic | -0.42 | -0.46 | -0.51 | -0.39 | -0.29 |
| Normalized Basic EPS | -0.26 | -0.29 | -0.32 | -0.24 | -0.18 |
| EPS Diluted | -0.42 | -0.46 | -0.51 | -0.39 | -0.29 |
| Normalized Diluted EPS | -0.26 | -0.29 | -0.32 | -0.24 | -0.18 |
| Average Basic Shares Outstanding | 10.76M | 10.76M | 10.74M | 10.73M | 10.86M |
| Average Diluted Shares Outstanding | 10.76M | 10.76M | 10.74M | 10.73M | 10.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
